Despite therapy with intravenous immunoglobulin (IVIG) plus infliximab, a monoclonal antibody against the pro- inflammatory cytokine tumor necrosis factor (TNF) ?, more than 25% of children with Kawasaki disease (KD), the most common cause of acquired heart disease in children, develop coronary artery abnormalities (CAA) with either dilated or aneurysmal coronary arteries. Once aneurysms have formed, the damage to the arterial wall is irreversible, and over time, stenoses and calcification may lead to ischemic complications. However, there is no recommended therapy to halt the progression of arterial wall damage and prevent aneurysm formation. Thus, the goal of our project is to test a new therapy to attenuate CAA and block progression of early injury to aneurysm formation. In KD, the IL-1 pathway is upregulated, as demonstrated by increased transcript abundance by microarray and by increased levels of pathway proteins in the plasma. In the Lactobacillus casei cell wall extract KD mouse model of coronary arteritis, the IL-1 receptor antagonist, anakinra, prevented the development of CAA, as did knocking out the IL-1 receptor. Given the role of the IL-1 pathway in KD-associated inflammation, blockade of IL-1 with anakinra is a logical therapy to attenuate CAA in KD. Treatment with anakinra has been well-tolerated and has coincided with a decrease in systemic inflammation and CAA in a small number of KD patients. However, despite its increasing off-label use, there are limited data in infants and young children. The proposed Phase I/IIa, dose escalation study will determine if anakinra in children at least 8 months to 17 years of age treated with IVIG and aspirin who have evidence of CAA by echocardiography is safe and well- tolerated (Specific Aim 1). Furthermore, this study will evaluate if anakinra has high bioavailability and whether its pharmacokinetics can be characterized by a one-compartment model using sparse sampling (Specific Aim 2). Lastly, this study will develop a pharmacodynamic biomarker-based model to find the proper dose of anakinra for a sustained anti-inflammatory effect in children with acute KD and CAAs. (Specific Aim3). Understanding the safety, PK, and proper dosing of anakinra to have a sustained anti-inflammatory effect are central to moving forward with a Phase III study and addressing the unmet clinical need of preventing formation or progression of aneurysms in KD.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54HD090259-01
Application #
9229403
Study Section
Special Emphasis Panel (ZHD1-DSR-Z (50))
Project Start
2016-09-20
Project End
2021-06-30
Budget Start
2016-09-20
Budget End
2017-06-30
Support Year
1
Fiscal Year
2016
Total Cost
$180,070
Indirect Cost
$63,896
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Bush, Kevin T; Wu, Wei; Lun, Christina et al. (2017) The drug transporter OAT3 (SLC22A8) and endogenous metabolite communication via the gut-liver-kidney axis. J Biol Chem 292:15789-15803
Caffrey, Aisling R; Timbrook, Tristan T; Noh, Eunsun et al. (2017) Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother 61:
Salgado, Andrea P; Ashouri, Negar; Berry, Erika K et al. (2017) High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. J Pediatr 185:112-116.e1
Wu, Wei; Bush, Kevin T; Nigam, Sanjay K (2017) Key Role for the Organic Anion Transporters, OAT1 and OAT3, in the in vivo Handling of Uremic Toxins and Solutes. Sci Rep 7:4939
Munguia, Jason; LaRock, Doris L; Tsunemoto, Hannah et al. (2017) The Mla pathway is critical for Pseudomonas aeruginosa resistance to outer membrane permeabilization and host innate immune clearance. J Mol Med (Berl) 95:1127-1136
Munguia, Jason; Nizet, Victor (2017) Pharmacological Targeting of the Host-Pathogen Interaction: Alternatives to Classical Antibiotics to Combat Drug-Resistant Superbugs. Trends Pharmacol Sci 38:473-488
Le, J; Dam, Q; Schweizer, M et al. (2016) Effects of vancomycin versus nafcillin in enhancing killing of methicillin-susceptible Staphylococcus aureus causing bacteremia by human cathelicidin LL-37. Eur J Clin Microbiol Infect Dis 35:1441-7
LaRock, Christopher N; Todd, Jordan; LaRock, Doris L et al. (2016) IL-1? is an innate immune sensor of microbial proteolysis. Sci Immunol 1:
Tremoulet, Adriana H; Jain, Sonia; Kim, Susan et al. (2016) Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial). Contemp Clin Trials 48:70-5
Rose, Warren E; Eickhoff, Jens C; Shukla, Sanjay K et al. (2012) Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia. J Infect Dis 206:1604-11